Value to the Fore: Flexible CRO Solutions Aim to Improve Pipeline Success
White Paper Apr 02, 2012
R&D outsourcing is widely used by pharmaceutical, biotechnology, agricultural and related industries. In order for this to continue, CRO's will need to make higher value contributions i collaborative drug discovery programs.
Trends indicate a return to value, as Contract Research Organizations (CROs) continue to grow their skill sets and ally with the global R&D industry to tap flexible solutions aimed at improving pipeline success. Bruce Molino, Ph.D., Senior Director of Medicinal Chemistry, and Christopher Conway, Senior Director of Business Development, AMRI, analyze the increasing demand for R&D outsourcing and examine how CROs are evolving to better meet industry needs.
Related White Papers
Using Micro Flow Imaging (MFI) to Measure Protein AggregationWhite Paper
Download this free white paper from Protein Simple to learn about the differences between MFI and how MFI provides crucial information about your protein therapeutic.READ MORE
Meeting Modern Data Integrity and Compliance RequirementsWhite Paper
The accuracy and completeness of data is crucial for safe product development and to prevent serious implications regarding human health.READ MORE
Big Data Lipidomics for Lipid Biomarker Identification and Drug DiscoveryWhite Paper
Data analysis process aiming at the identification of lipid biomarkers and the
evaluations of their performance.
World Advanced Therapies & Regenerative Medicine Congress
May 16 - May 18, 2018